Waste Reduction and Monetization Through the Establishment of a Subsidiary to Process and Sell Culture Supernatant
First written in FY2024-Q2. 3 of 6 entries say "Advanced", first in FY2024-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In December 2023, we established クオリプスヘルスケアサイエンス株式会社 as a consolidated subsidiary and are conducting research and development and planning for raw materials for healthcare products.」
The company continued describing the subsidiary’s business as research and development and planning for supplying raw materials to manufacturers and others, rather than processing and selling conditioned medium. - FY2025ReframedAnnual report
「In December 2023, we established クオリプスヘルスケアサイエンス株式会社 as a consolidated subsidiary and are advancing planning and research and development, including animal experiments, to supply raw materials to manufacturers and others.」
The subsidiary’s business description was reorganized from processing and selling conditioned medium and developing research-use reagents to research, development and planning for supplying raw materials to manufacturers and others. - FY2025-H1AdvancedAnnual report
「During the interim consolidated accounting period under review, in addition to developing research-use cell-culture conditioned-medium reagents for clinics and cosmetics companies, we filed a patent application for the manufacturing method.」
The conditioned-medium business progressed to development of research-use reagents for clinics and cosmetics companies and filing of a manufacturing-method patent application. - FY2024AdvancedAnnual report
「We established a subsidiary to sell conditioned medium and other products in order to use culture fluid after cell culture effectively and generate stable revenue, and proceeded to develop customers.」
Following establishment of the subsidiary, the company moved to the stage of developing customers for conditioned medium. No sales results or achievement of stable revenue generation were reported. - FY2024-Q3AdvancedAnnual report
「To reduce waste generated during cell culture and generate stable revenue, we established a subsidiary to sell conditioned medium that had previously constituted part of the waste.」
クオリプスヘルスケアサイエンス株式会社 was established on 8 December 2023 and became a consolidated subsidiary from the third quarter. The planned subsidiary-establishment milestone was achieved, but no sales results or completion of stable revenue generation were reported. - FY2024-Q2First statedAnnual report
「We will establish the subsidiary to reduce waste generated during cell culture and generate stable revenue through the processing and sale of conditioned medium, part of which had previously been treated as waste. Capital: ¥30.000 million. Planned establishment: December 2023.」
At a Board of Directors meeting on 10 November 2023, the company resolved to establish a wholly owned subsidiary to process and sell conditioned medium. The purposes were to reduce waste and generate stable revenue.